

**Information notice on
the conclusion of a related party agreement
pursuant to article L. 22-10-13 of the French Commercial Code**

Subscription agreement of royalty certificates
(Authorised by the Board of Directors on 16 July 2024)

Daix, July 18th, 2024 - Pursuant to Articles L. 22-10-13 and R 22-10-17 of the French Commercial Code, Inventiva S.A. (the "Company") points out that on July 17th, 2024 it signed a Royalty Certificate Subscription Agreement with Biotechnology Value Fund Partners L.P., acting on behalf of several funds and entities managed by it ('BVF').

Purpose: As part of the Company's financing operations, the Company issued two hundred and one (201) royalty certificates (the 'Certificates'). Five investors subscribed to these Certificates. Among these investors, BVF, which holds more than ten per cent of the Company's voting rights, subscribed to sixty-four (64) Certificates in consideration of a total price of six million four hundred thousand euros (€6,400,000).

Financial conditions: Under the terms of the Certificates subscription agreement, BVF undertakes to pay the Company one hundred thousand euros (€100,000) per Certificate on July 22nd, 2024 (the date scheduled for settlement-delivery of the Certificates), i.e. a total of six million four hundred thousand euros (€6,400,000) for sixty-four (64) Certificates.

As announced by the Company in a July 18th, 2024 press release, the main features of this financing transaction are as follows:

The Certificates entitle their holders to the annual payment of royalties (the 'Royalties') in an amount equal to three percent (3%) of future net sales of lanifibranor (the 'Product'), if any, commencing in the financial year following the commencement of sales of the Product following the potential grant of marketing authorisation for the Product in (i) the United States of America or (ii) the countries of the European Union or (iii) the United Kingdom, whichever occurs first.

The Certificates have a maturity of fourteen (14) years from the date of issue and are not redeemable early in the event of a change of control. Holders of Certificates are subject to a six (6) month lock-up period, at the end of which the Certificates will become freely transferable (in whole or in part, provided that the transfer relates to a minimum number of ten (10) Certificates) solely pursuant to an exemption from the registration requirements of the U.S. Securities Act, 1933, as amended, (the 'Securities Act') and to qualified investors pursuant to Article 2(e) of Regulation (EU) 2017/1129. The Company has rights of redemption and pre-emption in respect of the Certificates.

Person concerned: Biotechnology Value Fund Partners L.P., acting on behalf of a number of funds and entities BVF manages, which together hold more than 10% of the Company's voting rights.

Reasons why it is in the Company's interest to enter into the Agreement: The conclusion of the agreement, which is part of a broader financing transaction (see the Company's July 18th, 2024 press release), will provide the Company with cash flow enabling it to finance its operations until the end of September 2024.

Agreement approval procedures: The Company's Board of Directors authorised the conclusion of the agreement during its July 16th, 2024 meeting. The agreement will be submitted for ratification at the next General Meeting of the Company's shareholders.

* * *